News

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results ...
S&P500 holds flat as traders eye Fed’s rate decision, strong GDP data, and Big Tech earnings. Market sentiment hinges on ...
SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...
Volatility: Blue chip stocks are usually less volatile than other stocks.
Pfizer Inc. (NYSE: PFE) delivered a stronger-than-anticipated second-quarter performance, beating analyst estimates and ...
Pfizer Inc. (NYSE: PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the ...
At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...
Trump Media shares dipped after launching its AI-powered Truth Search beta with Perplexity, even as the company reported $3.1 ...
While Pfizer remains on track for an impressive $7.2 billion in cost cuts by the end of 2027, we think the market is more ...
Pfizer Inc displayed a robust performance in its Q2 2025 earnings call, with significant strides in revenue and research ...
Central to Nxera’s pipeline is its new, wholly owned oral small molecule GLP-1 agonist program, focussed on differentiated chemistry, which is distinct, independent and developed separately from ...
Live Updates Live Coverage Has Ended Tuesday Wrap-up 4:27 pm The Vanguard S&P 500 ETF closed at 577.35 Tuesday, down 0.5%.